Awachana Jiamsakul1, Mark Boyd2, Jun Yong Choi3, Natalie Edmiston4,5,6, Nagalingeswaran Kumarasamy7, Jolie Hutchinson1, Matthew Law1, Rossana Ditangco8. 1. The Kirby Institute, UNSW, Sydney, Australia. 2. School of Medicine, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia. 3. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 4. Faculty of Medicine and Health, University of Sydney, Sydney, Australia. 5. HIV/Sexual Health Services North Coast Public Health, Mid North Coast Local Health District, Lismore, Australia. 6. Rural Research, Western Sydney University, Sydney, Australia. 7. Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), the Voluntary Health Services (VHS), Chennai, India; and. 8. Research Institute for Tropical Medicine, Manila, Philippines.
Abstract
BACKGROUND: Less frequent follow-up visits may reduce the burden on people living with HIV (PLHIV) and health care facilities. We aimed to assess trends in follow-up visits and survival outcomes among PLHIV in Asia and Australasia. SETTINGS: PLHIV enrolled in TREAT Asia HIV Observational Database (TAHOD) or Australian HIV Observational Database (AHOD) from 2008 to 2017 were included. METHODS: Follow-up visits included laboratory testing and clinic visit dates. Visit rates and survival were analyzed using repeated measure Poisson regression and competing risk regression, respectively. Additional analyses were limited to stable PLHIV with viral load <1000 copies/mL and self-reported adherence ≥95%. RESULTS: We included 7707 PLHIV from TAHOD and 3289 PLHIV from AHOD. Visit rates were 4.33 per person-years (/PYS) in TAHOD and 3.68/PYS in AHOD. Both TAHOD and AHOD showed decreasing visit rates in later calendar years compared with that in years 2008-2009 (P < 0.001 for both cohorts). Compared with PLHIV with 2 visits, those with ≥4 visits had poorer survival: TAHOD ≥4 visits, subhazard ratio (SHR) = 1.88, 95% confidence interval (CI): 1.16 to 3.03, P = 0.010; AHOD ≥4 visits, SHR = 1.80, 95% CI: 1.10 to 2.97, P = 0.020; whereas those with ≤1 visit showed no differences in mortality. The association remained evident among stable PLHIV: TAHOD ≥4 visits, SHR = 5.79, 95% CI: 1.84 to 18.24, P = 0.003; AHOD ≥4 visits, SHR = 2.15, 95% CI: 1.20 to 3.85, P = 0.010, compared with 2 visits. CONCLUSIONS: Both TAHOD and AHOD visit rates have declined. Less frequent visits did not affect survival outcomes; however, poorer health possibly leads to increased follow-up and higher mortality. Reducing visit frequency may be achievable among PLHIV with no other medical complications.
BACKGROUND: Less frequent follow-up visits may reduce the burden on people living with HIV (PLHIV) and health care facilities. We aimed to assess trends in follow-up visits and survival outcomes among PLHIV in Asia and Australasia. SETTINGS: PLHIV enrolled in TREAT Asia HIV Observational Database (TAHOD) or Australian HIV Observational Database (AHOD) from 2008 to 2017 were included. METHODS: Follow-up visits included laboratory testing and clinic visit dates. Visit rates and survival were analyzed using repeated measure Poisson regression and competing risk regression, respectively. Additional analyses were limited to stable PLHIV with viral load <1000 copies/mL and self-reported adherence ≥95%. RESULTS: We included 7707 PLHIV from TAHOD and 3289 PLHIV from AHOD. Visit rates were 4.33 per person-years (/PYS) in TAHOD and 3.68/PYS in AHOD. Both TAHOD and AHOD showed decreasing visit rates in later calendar years compared with that in years 2008-2009 (P < 0.001 for both cohorts). Compared with PLHIV with 2 visits, those with ≥4 visits had poorer survival: TAHOD ≥4 visits, subhazard ratio (SHR) = 1.88, 95% confidence interval (CI): 1.16 to 3.03, P = 0.010; AHOD ≥4 visits, SHR = 1.80, 95% CI: 1.10 to 2.97, P = 0.020; whereas those with ≤1 visit showed no differences in mortality. The association remained evident among stable PLHIV: TAHOD ≥4 visits, SHR = 5.79, 95% CI: 1.84 to 18.24, P = 0.003; AHOD ≥4 visits, SHR = 2.15, 95% CI: 1.20 to 3.85, P = 0.010, compared with 2 visits. CONCLUSIONS: Both TAHOD and AHOD visit rates have declined. Less frequent visits did not affect survival outcomes; however, poorer health possibly leads to increased follow-up and higher mortality. Reducing visit frequency may be achievable among PLHIV with no other medical complications.
Authors: April Buscher; Michael Mugavero; Andrew O Westfall; Jeanne Keruly; Richard Moore; Mari-Lynn Drainoni; Meg Sullivan; Tracey E Wilson; Allan Rodriguez; Lisa Metsch; Lytt Gardner; Gary Marks; Faye Malitz; Thomas P Giordano Journal: AIDS Patient Care STDS Date: 2013-07-26 Impact factor: 5.078
Authors: Hamish McManus; Kathy Petoumenos; Katherine Brown; David Baker; Darren Russell; Tim Read; Don Smith; Lynne Wray; Michelle Giles; Jennifer Hoy; Andrew Carr; Matthew G Law Journal: Antivir Ther Date: 2014-11-07
Authors: A Jiamsakul; S Kiertiburanakul; O T Ng; R Chaiwarith; W Wong; R Ditangco; K V Nguyen; A Avihingsanon; S Pujari; C D Do; M-P Lee; P S Ly; E Yunihastuti; N Kumarasamy; A Kamarulzaman; J Tanuma; F Zhang; J Y Choi; P Kantipong; Blh Sim; J Ross; M Law; T P Merati Journal: HIV Med Date: 2019-04-12 Impact factor: 3.180
Authors: Michael A Horberg; Leo B Hurley; Michael J Silverberg; Daniel B Klein; Charles P Quesenberry; Michael J Mugavero Journal: AIDS Patient Care STDS Date: 2013-07-19 Impact factor: 5.078
Authors: Andreas D Haas; Leigh F Johnson; Anna Grimsrud; Nathan Ford; Catarina Mugglin; Matthew P Fox; Jonathan Euvrard; Monique van Lettow; Hans Prozesky; Izukanji Sikazwe; Cleophas Chimbetete; Michael Hobbins; Cordelia Kunzekwenyika; Matthias Egger Journal: J Acquir Immune Defic Syndr Date: 2019-08-01 Impact factor: 3.731
Authors: Jialun Zhou; N Kumarasamy; Rossana Ditangco; Adeeba Kamarulzaman; Christopher K C Lee; Patrick C K Li; Nicholas I Paton; Praphan Phanuphak; Sanjay Pujari; Asda Vibhagool; Wing-Wai Wong; Fujie Zhang; John Chuah; Kevin R Frost; David A Cooper; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2005-02-01 Impact factor: 3.771
Authors: Viet-Thi Tran; Eugene Messou; Mariam Mama Djima; Philippe Ravaud; Didier K Ekouevi Journal: BMJ Qual Saf Date: 2018-04-29 Impact factor: 7.035
Authors: Mia L van der Kop; Patrick I Nagide; Lehana Thabane; Lawrence Gelmon; Lennie B Kyomuhangi; Bonface Abunah; Anna Mia Ekström; Richard T Lester Journal: J Int AIDS Soc Date: 2018-11 Impact factor: 5.396